Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

NCT ID: NCT07322718

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-24
• Study Completion Date: 2028-03-19

Brief Summary

This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.

Detailed Description

This Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of RXIM002 in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases. Eligible participants will receive intravenous administration of RXIM002 and will be monitored for adverse events, laboratory parameters, and other safety outcomes. The study will also explore biological activity and potential clinical responses across the enrolled autoimmune conditions. Participants will be followed for a defined period after treatment to assess longer-term safety and durability of any observed effects. The study will include the following sequential phases: screening, treatment, and follow-up.

Conditions

Relapsed/Refractory B Cell-Mediated Autoimmune Diseases

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RXIM002

Each study participant will be given 2 doses of RXIM002 at each dose level.

Group Type: EXPERIMENTAL

RXIM002 product

Intervention Type: BIOLOGICAL

Prior to infusion of the RXIM002 product, subjects will receive pre-medication if needed

Interventions

RXIM002 product

Prior to infusion of the RXIM002 product, subjects will receive pre-medication if needed

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Subjects voluntary agreement to provide written informed consent.
• Aged 18 to 65 years, either sex.
• Adequate organ function meeting screening criteria.
• Positive test for cluster of differentiation antigen 19 (CD19).

Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN):

• Have been diagnosed with SLE or LN before screening.
• Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), antinuclear antibody (ANA), or anti-Sm antibodies at screening.
• Active disease at screening.
• Fulfill relapsed/refractory SLE or LN conditions

Lupus Nephritis (LN) :

• Kidney biopsy result indicating LN
• Evidence of LN disease activity

Systemic Sclerosis (SSc):

• Have been diagnosed with SSc before screening.
• Antinuclear Antibody (ANA) positive at screening or prior to screening. AND, evidence of SSc disease activity.
• Fulfill relapsed/refractory SSc conditions.

Immune Thrombocytopenia (ITP):

• Have been diagnosed with refractory ITP before screening.
• Platelet count <50×10⁹/L at screening.

Idiopathic Inflammatory Myopathy (IIM):

• Have been diagnosed with IIM before screening.
• Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.
• Evidence of IIM disease activity.
• Fulfill relapsed/refractory IIM conditions.

Membranous Nephropathy (MN):

• Have been diagnosed with MN before screening.
• Active MN patients meeting screening criteria.
• Fulfill relapsed/refractory MN conditions.

Autoimmune Hemolytic Anemia (AIHA):

• Have been diagnosed with AIHA before screening.
• Active AIHA patients meeting screening criteria.
• Fulfill relapsed/refractory AIHA conditions.

Exclusion Criteria

• Active infections such as hepatitis and tuberculosis.
• Other autoimmune diseases.
• Serious underlying diseases such as active malignancies, uncontrolled diabetes.
• Female subjects who were pregnant, breastfeeding.
• Any uncontrolled psychiatric disorders (e.g., schizophrenia, bipolar disorder, eating disorders, major depression or anxiety disorder), as declared by the participant or reported in the medical records.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RiboX Therapeutics Ltd.

INDUSTRY

Sponsor Role: collaborator

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Ruijin Hospital

Shanghai, Huangpu District, China

Site Status: RECRUITING

Countries

China

Central Contacts

Qiongyi Hu

Role: CONTACT

huqiongyi131@163.com

+86 021-50199835

Facility Contacts

Hu Qiongyi Hu Qiongyi, Doctor

Role: primary

huqiongyi131@163.com

086+15062338287

Other Identifiers

RX-AID-CS101

Identifier Type: -

Identifier Source: org_study_id